中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝纤维化相关信号通路及其相应的抗肝纤维化药物研究进展

鲁苏日古嘎 刘霆 朱单单 余思佳 卢礼卿 丁俊杰

引用本文:
Citation:

肝纤维化相关信号通路及其相应的抗肝纤维化药物研究进展

DOI: 10.3969/j.issn.1001-5256.2022.05.039
基金项目: 

国家自然科学基金 (82070632)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:鲁苏日古嘎负责资料收集及文章撰写; 朱单单、刘霆、卢礼卿、余思佳、丁俊杰参与修改文章内容。
详细信息
    通信作者:

    刘霆,liuting818@126.com

Research advances in hepatic fibrosis related signal pathways and anti-hepatic fibrosis drugs

Research funding: 

National Natural Science Foundation of China (82070632)

More Information
  • 摘要: 肝纤维化是肝脏长期受到各种急、慢性损伤导致肝星状细胞激活、细胞外基质生成与降解失衡并在肝脏沉积的一种病理学过程,受多条细胞信号转导通路和一系列细胞信息分子网络共同控制。如未行有效的治疗干预,随着病情的发展形成肝纤维结节并破坏正常的肝脏结构与功能,最终发展为肝硬化,出现肝功能的衰退,甚至演变为肝癌。本文着重介绍目前研究较明确和相对热点的肝纤维化信号通路、受体、非编码RNA及其对应的抗肝纤维化药物/分子的研究进展。

     

  • 图  1  肝纤维化信号传导通路图

    注:多种细胞信号传导通路构成复杂的网络,共同参与了肝纤维化的发生和发展。细胞膜上受体接受信号刺激后,通过其信号通路下游靶点传达信号,最终在细胞核调节多个肝纤维化相关靶基因的表达。miRNA等非编码RNA也参与这些信号传导,或促进或抑制肝纤维化。Col1a1:表达Ⅰ型胶原蛋白; Col3a1:表达Ⅲ型胶原蛋白。

    Figure  1.  Diagram of hepatic fibrosis signaling pathways

  • [1] HIGASHI T, FRIEDMAN SL, HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121: 27-42. DOI: 10.1016/j.addr.2017.05.007.
    [2] FRIEDMAN SL. Molecular mechanisms of hepatic fibrosis and principles of therapy[J]. J Gastroenterol, 1997, 32(3): 424-430. DOI: 10.1007/BF02934504.
    [3] DERYNCK R, BUDI EH. Specificity, versatility, and control of TGF-β family signaling[J]. Sci Signal, 2019, 12(570): eaav5183. DOI: 10.1126/scisignal.aav5183.
    [4] LIU J, KONG D, QIU J, et al. Praziquantel ameliorates CCl4-induced liver fibrosis in mice by inhibiting TGF-β/Smad signalling via up-regulating Smad7 in hepatic stellate cells[J]. Br J Pharmacol, 2019, 176(24): 4666-4680. DOI: 10.1111/bph.14831.
    [5] NI XX, LI XY, WANG Q, et al. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH via TGF-β1/Smad signaling pathway[J]. J Physiol Biochem, 2021, 77(1): 35-45. DOI: 10.1007/s13105-020-00777-7.
    [6] OGAWA H, KAJI K, NISHIMURA N, et al. Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis[J]. J Cell Mol Med, 2021, 25(8): 4001-4013. DOI: 10.1111/jcmm.16363.
    [7] ZHANG W, YANG GY, SHEN DX, et al. Mechanism of action of Xiayuxue decoction in inhibiting liver fibrosis by regulating glial cell line -derived neurotrophic factor[J]. J Clin Hepatol, 2021, 37(3): 575-581. DOI: 10.3969/j.issn.1001-5256.2021.03.015.

    张玮, 杨广越, 沈东晓, 等. 下瘀血汤抑制胶质细胞源性神经营养因子抗肝纤维化的作用机制[J]. 临床肝胆病杂志, 2021, 37(3): 575-581. DOI: 10.3969/j.issn.1001-5256.2021.03.015.
    [8] CHOI S, JUNG HJ, KIM MW, et al. A novel STAT3 inhibitor, STX-0119, attenuates liver fibrosis by inactivating hepatic stellate cells in mice[J]. Biochem Biophys Res Commun, 2019, 513(1): 49-55. DOI: 10.1016/j.bbrc.2019.03.156.
    [9] LYU L, YIN JK, ZHANG Z, et al. Role of ruxolitinib in the target inhibition of hepatic stellate cell activation and mechanism[J]. J Shanxi Med Univ, 2020, 51(2): 141-146. DOI: 10.13753/j.issn.1007-6611.2020.02.007.

    律玲, 阴继凯, 张章, 等. 芦可替尼靶向抑制肝星状细胞活化的作用及机制[J]. 山西医科大学学报, 2020, 51(2): 141-146. DOI: 10.13753/j.issn.1007-6611.2020.02.007.
    [10] SU TH, SHIAU CW, JAO P, et al. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition[J]. Proc Natl Acad Sci U S A, 2015, 112(23): 7243-7248. DOI: 10.1073/pnas.1507499112.
    [11] DENG YR, MA HD, TSUNEYAMA K, et al. STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib[J]. J Autoimmun, 2013, 46: 25-34. DOI: 10.1016/j.jaut.2013.07.008.
    [12] MARTÍ-RODRIGO A, ALEGRE F, MORAGREGA ÁB, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5): 920-932. DOI: 10.1136/gutjnl-2019-318372.
    [13] PERUGORRIA MJ, OLAIZOLA P, LABIANO I, et al. Wnt-β-catenin signalling in liver development, health and disease[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(2): 121-136. DOI: 10.1038/s41575-018-0075-9.
    [14] RAO S, XIANG J, HUANG J, et al. PRC1 promotes GLI1-dependent osteopontin expression in association with the Wnt/β-catenin signaling pathway and aggravates liver fibrosis[J]. Cell Biosci, 2019, 9: 100. DOI: 10.1186/s13578-019-0363-2.
    [15] RONG X, LIU J, YAO X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J]. Stem Cell Res Ther, 2019, 10(1): 98. DOI: 10.1186/s13287-019-1204-2.
    [16] ZHANG M, HAUGHEY M, WANG NY, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs[J]. PLoS One, 2020, 15(3): e0229445. DOI: 10.1371/journal.pone.0229445.
    [17] ZHU C, KIM K, WANG X, et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis[J]. Sci Transl Med, 2018, 10(468): eaat0344. DOI: 10.1126/scitranslmed.aat0344.
    [18] RICHTER LR, WAN Q, WEN D, et al. Targeted delivery of Notch inhibitor attenuates obesity-induced glucose intolerance and liver fibrosis[J]. ACS Nano, 2020, 14(6): 6878-6886. DOI: 10.1021/acsnano.0c01007.
    [19] ESMAIL MM, SAEED NM, MICHEL HE, et al. The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways[J]. Toxicol Lett, 2021, 347: 23-35. DOI: 10.1016/j.toxlet.2021.04.018.
    [20] DAVEY MG, MCTEIR L, BARRIE AM, et al. Loss of cilia causes embryonic lung hypoplasia, liver fibrosis, and cholestasis in the talpid3 ciliopathy mutant[J]. Organogenesis, 2014, 10(2): 177-185. DOI: 10.4161/org.28819.
    [21] GU S, YAN M, WANG C, et al. Microcystin-leucine-arginine induces liver fibrosis by activating the Hedgehog pathway in hepatic stellate cells[J]. Biochem Biophys Res Commun, 2020, 533(4): 770-778. DOI: 10.1016/j.bbrc.2020.09.075.
    [22] FENG J, WANG C, LIU T, et al. Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the Hedgehog pathway during liver fibrosis[J]. J Cell Mol Med, 2019, 23(9): 6479-6493. DOI: 10.1111/jcmm.14543.
    [23] SHEN JY, YAN JY, WEI XZ, et al. Gant61 ameliorates CCl4-induced liver fibrosis by inhibition of Hedgehog signaling activity[J]. Toxicol Appl Pharmacol, 2020, 387: 114853. DOI: 10.1016/j.taap.2019.114853.
    [24] FIORUCCI S, ANTONELLI E, RIZZO G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis[J]. Gastroenterology, 2004, 127(5): 1497-1512. DOI: 10.1053/j.gastro.2004.08.001.
    [25] FIORUCCI S, RIZZO G, ANTONELLI E, et al. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis[J]. J Pharmacol Exp Ther, 2005, 314(2): 584-595. DOI: 10.1124/jpet.105.084905.
    [26] YOUNOSSI Z M, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. DOI: 10.1016/S0140-6736(19)33041-7.
    [27] WANG Y, NAKAJIMA T, GONZALEZ FJ, et al. PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-null mice[J]. Int J Mol Sci, 2020, 21(6) : 2061. DOI: 10.3390/ijms21062061.
    [28] KLAVDIANOU K, LIOSSIS SN, SAKKAS L, et al. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma?[J]. Semin Arthritis Rheum, 2017, 46(4): 430-438. DOI: 10.1016/j.semarthrit.2016.08.014.
    [29] KUMAR DP, CAFFREY R, MARIONEAUX J, et al. The PPAR α/γ agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease[J]. Sci Rep, 2020, 10(1): 9330. DOI: 10.1038/s41598-020-66458-z.
    [30] MARRA F, DEFRANCO R, ROBINO G, et al. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis[J]. World J Gastroenterol, 2005, 11(32): 4931-4938. DOI: 10.3748/wjg.v11.i32.4931.
    [31] CHEN W, YAN X, YANG A, et al. miRNA-150-5p promotes hepatic stellate cell proliferation and sensitizes hepatocyte apoptosis during liver fibrosis[J]. Epigenomics, 2020, 12(1): 53-67. DOI: 10.2217/epi-2019-0104.
  • 肝纤维化相关信号通路及其相应的抗肝纤维化药物研究进展-附录.pdf
  • 加载中
图(1)
计量
  • 文章访问数:  571
  • HTML全文浏览量:  452
  • PDF下载量:  92
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-09-07
  • 出版日期:  2022-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回